Entrada Therapeutics reported financial results for the first quarter ended March 31, 2025, on May 8, 2025. Cash, cash equivalents, and marketable securities were $382.5 million as of March 31, 2025, a decrease from $420.0 million at December 31, 2024, primarily due to cash used in operations. The company maintains a projected cash runway into Q2 2027.
Collaboration revenue for Q1 2025 was $20.6 million, compared to $59.1 million for the same period in 2024. Research & Development (R&D) expenses increased to $32.1 million for Q1 2025 from $28.6 million in Q1 2024, driven by costs related to Duchenne programs and higher personnel costs. The net loss for Q1 2025 was $(17.3) million, a shift from a net income of $23.5 million in Q1 2024.
The company announced European Union regulatory clearance for ELEVATE-44-201, the Phase 1/2 MAD clinical study of ENTR-601-44. Entrada remains on track to initiate ELEVATE-44-201 in Q2 2025 and ELEVATE-45-201 in Q3 2025. The company expects to advance three distinct Duchenne programs (exon 44, 45, and 50 skip amenable) into global clinical development by the end of 2025, with the partnered VX-670 program also progressing.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.